Angiodynamics enrolls first patient in ambition btk trial advancing treatment for critical limb ischemia

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the randomized study of the auryon atherectomy system used in combination with standard balloon angioplasty versus standard balloon angioplasty alone treating infrapopliteal lesions in subjects with critical.
ANGO Ratings Summary
ANGO Quant Ranking